November 13, 2020
Sagent Pharmaceuticals, a US subsidiary of Nichi-Iko Pharmaceutical, has commenced a PII study to investigate the safety and efficacy of the protease inhibitor camostat mesilate for the treatment of COVID-19 in high-risk outpatients. The CAMELOT trial in the US has...read more